Results 301 to 310 of about 77,471 (339)

Cancer-Associated PIK3CA Mutations in Overgrowth Disorders [PDF]

Trends in Molecular Medicine, 2018
PIK3CA is one of the most commonly mutated genes in solid cancers. PIK3CA mutations are also found in benign overgrowth syndromes, collectively known as PIK3CA-related overgrowth spectrum (PROS).
Robert K Semple, Ralitsa R Madsen, Bart Vanhaesebroeck   +2 more
exaly   +5 more sources

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer

Annals of Oncology, 2020
BACKGROUND α-Selective phosphatidylinositol 3-kinase (PI3K) inhibitors improve outcome in patients with PIK3CA-mutated, hormone receptor-positive (HR+)/Her2- metastatic breast cancer (mBC). Nevertheless, it is still unclear how to integrate this new drug
Fabrice André, C Jovelet, J -C Soria
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

The PIK3CA-E545K-SIRT4 signaling axis reduces radiosensitivity by promoting glutamine metabolism in cervical cancer.

Cancer Letters, 2023
The mutation of glutamic acid 545 to lysine (E545K) in PIK3CA, as the most common missense mutation of this gene in various cancer types, is frequently observed in cervical cancer and has been shown to reduce cervical cancer radiosensitivity.
Wei-Wei Jiang, Xueyan Ouyang, Zha Ji, Wanling Shi, Yutuan Wu, Qianlan Yao, Yi Wang, Wentao Yang, L. Xiang, Hui-Juan Yang   +9 more
semanticscholar   +1 more source

KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics.

Critical reviews in oncology/hematology, 2023
BACKGROUND Colorectal cancer is one of the most prevalent malignancies and its molecular pathogenesis has been intensely investigated for several decades. As a result, great progress has been made and targeted therapies have been introduced in the clinic.
I. Voutsadakis
semanticscholar   +1 more source

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.

The Lancet Oncology
BACKGROUND Alpelisib, a PI3Kα-selective inhibitor and degrader, plus fulvestrant showed efficacy in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer in SOLAR-1; limited data are available in the post-cyclin-dependent kinase
H. Rugo, F. Lerebours, E. Ciruelos, P. Drullinsky, M. Ruíz-Borrego, P. Neven, Yeon-Hee Park, A. Prat, T. Bachelot, D. Juric, N. Turner, N. Sophos, J. P. Zarate, C. Arce, Yu-ming Shen, Stuart J. Turner, H. Kanakamedala, Wei-Chun Hsu, S. Chia   +18 more
semanticscholar   +1 more source

PIK3CA mutations in glioblastoma multiforme

Acta Neuropathologica, 2005
Glioblastoma multiforme WHO grade IV is the most common and malignant variant of astrocytic tumors. Loss of heterozygosity of chromosome 10 and mutations in the tumor suppressor gene PTEN on 10q are molecular hallmarks of glioblastomas. Recently, mutations were identified in PIK3CA, encoding a protein that antagonizes the function of PTEN protein in ...
Christian, Hartmann, Gesine, Bartels, Claire, Gehlhaar, Nikola, Holtkamp, Andreas, von Deimling   +4 more
openaire   +2 more sources

Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.

New England Journal of Medicine
BACKGROUND Inavolisib is a highly potent and selective inhibitor of the alpha isoform of the p110 catalytic subunit of the phosphatidylinositol 3-kinase complex (encoded by PIK3CA) that also promotes the degradation of mutated p110α.
N. Turner, Seock-Ah Im, C. Saura, D. Juric, S. Loibl, K. Kalinsky, P. Schmid, S. Loi, P. Sunpaweravong, A. Musolino, Hui-Ping Li, Qingyuan Zhang, Z. Nowecki, R. Leung, E. Thanopoulou, N. Shankar, G. Lei, T. Stout, K. Hutchinson, J. Schutzman, Chunyan Song, K. Jhaveri   +21 more
semanticscholar   +1 more source

Somatic PIK3CA mutations in seven patients with PIK3CA‐related overgrowth spectrum

American Journal of Medical Genetics Part A, 2017
Somatic mutations in PIK3CA cause many overgrowth syndromes that have been recently coined the “PIK3CA‐Related Overgrowth Spectrum.” Here, we present seven molecularly confirmed patients with PIK3CA‐Related Overgrowth Spectrum, including patients with Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevi, Scoliosis/Skeletal and ...
Tam, PKH, Kuong, EEYL, Ip, JKJ, Chow, CP, YEUNG, KS, Chung, BHY, Chan, GCF   +6 more
openaire   +4 more sources

The role of PIK3CA gene mutations in colorectal cancer and the selection of treatment strategies

Frontiers in Pharmacology
PIK3CA gene encodes the p110α catalytic subunit of PI3K, which regulates the PI3K/AKT/mTOR signaling pathway. PIK3CA gene mutation is one of the most common mutations in colorectal cancer (CRC), affecting about 15%–20% of CRC patients.
Haitao Wang, Rui Tang, Ling Jiang, Yingtian Jia   +3 more
semanticscholar   +1 more source

Electrochemical Biosensor Based on l-Arginine and rGO-AuNSs Deposited on the Electrode Combined with DNA Probes for Ultrasensitive Detection of the Gastric Cancer-Related PIK3CA Gene of ctDNA.

ACS Applied Bio Materials, 2022
Gene biomarkers of circulating tumor DNA (ctDNA) in liquid biopsies have been explored for use in the precise diagnosis of tumors. There is a great clinical need to realize the ultrasensitive detection of gene biomarkers in ctDNA.
Mahbubur Rahman, Jiaqi Niu, Xin-Yuan Cui, Cheng Zhou, Ning Tang, Han Jin, Da-Xiang Cui   +6 more
semanticscholar   +1 more source